Synaptogenix (NASDAQ:TAOX) Releases Quarterly Earnings Results

Synaptogenix (NASDAQ:TAOX) announced its quarterly earnings results on Thursday. The company reported ($1.83) earnings per share (EPS) for the quarter, Zacks reports. Synaptogenix had a negative return on equity of 116.74% and a negative net margin of 2,153.97%.The company had revenue of $0.09 million for the quarter.

Synaptogenix Price Performance

Shares of Synaptogenix stock traded down $0.04 during trading on Friday, hitting $3.44. The company’s stock had a trading volume of 57,160 shares, compared to its average volume of 91,081. The stock has a market cap of $25.70 million, a price-to-earnings ratio of -0.26 and a beta of 1.45. Synaptogenix has a 52 week low of $3.18 and a 52 week high of $10.00. The stock has a 50-day moving average price of $3.61 and a two-hundred day moving average price of $4.41.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TAOX. Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a research report on Friday, July 17th. Wall Street Zen raised Synaptogenix from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.